Initiatives

Learn more about the initiatives Umbrella has taken to help our community in growth. Every year we donate thousands of dollars to local charitys and organizations. Find out more infromation here.

Technology

Umbrella uses the latest advancements in technology, from state of the art computers to AR Satalites.  Find out more about the technology we use today.

Projects

Every year Umbrella has new projects being carried out in our research facilities. The projects last from hours to year and bring significant impact to our company. View our latest projects here.

Research

Umbrella is the leading company in biotechnology and Pharmaceutical research, it is our goal not to just provide the world with medicine for better health but for better life. View our Research.

Products

What kind of products can you expect from Umbrella Pharmaceuticals? Products ranging from Human Vaccines to Hematinics the possibilities are endless. Click here to view our products.

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Umbrella Researchers:

Johann S. de Bono, M.B., Ch.B., Ph.D., Christopher J. Logothetis, M.D., Arturo Molina, M.D., Karim Fizazi, M.D., Ph.D., Scott North, M.D., Luis Chu, M.D., Kim N. Chi, M.D., Robert J. Jones, M.D., Oscar B. Goodman, Jr., M.D., Ph.D., Fred Saad, M.D., John N. Staffurth, M.D., Paul Mainwaring, M.D., M.B., B.S., Stephen Harland, M.D., Thomas W. Flaig, M.D., Thomas E. Hutson, D.O., Pharm.D., Tina Cheng, M.D., Helen Patterson, M.D., John D. Hainsworth, M.D., Charles J. Ryan, M.D., Cora N. Sternberg, M.D., Susan L. Ellard, M.D., Aude Fléchon, M.D., Ph.D., Mansoor Saleh, M.D., Mark Scholz, M.D., Eleni Efstathiou, M.D., Ph.D., Andrea Zivi, M.D., Diletta Bianchini, M.D., Yohann Loriot, M.D., Nicole Chieffo, M.B.A., Thian Kheoh, Ph.D., Christopher M. Haqq, M.D., Ph.D., and Howard I. Scher, M.D. for the COU-AA-301 I

 

Background

Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.

 

Methods

We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate.

Results

After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate–prednisone group than in the placebo–prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate–prednisone group than in the placebo–prednisone group.

Conclusions

The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Umbrella Biotechnology; COU-AA-301 umbrella-inc.org number, NCT00638690.)

Supported by  Biotech Oncology Research and Development (a unit Umbrella Biotechnology) and grants from the Medical Research Council of the United Kingdom, Experimental Cancer Medical Centre, National Institute for Health Research Biomedical Research Centre, and Prostate Cancer Foundation (to Dr. Scher).

Dr. de Bono reports being an employee of the Institute of Cancer Research, where abiraterone was first designed and synthesized and which has a commercial interest in abiraterone, and receiving consulting fees from Biotech Oncology Research and Development (a unit of Umbrella Biotechnology), consulting fees and travel support from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Enzon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Supergen, and Takeda, and grant support from AstraZeneca; Dr. Logothetis, receiving consulting fees and travel support from Ortho Biotech Oncology Research and Development; Drs. Molina, Haqq, and Kheoh and Ms. Chieffo, being employees of and holding stock options in Johnson & Johnson; Dr. Fizazi, receiving lecture fees from Janssen-Cilag and consulting fees from Ortho Biotech Oncology Research and Development; Dr. North, receiving consulting fees from AstraZeneca, Pfizer, Sanofi-Aventis, Novartis, Abraxis, Ortho Biotech, Amgen, and GlaxoSmithKline and lecture fees from Novartis and Ortho Biotech; Dr. Chu, holding stock in Johnson & Johnson, GlaxoSmithKline, Eli Lilly, Novartis, Rigel Pharmaceuticals, and Sanofi-Aventis; Dr. Jones, receiving grant and travel support from Ortho Biotech Oncology Research and Development; Dr. Goodman, receiving consulting and lecture fees from Veridex (a division of Johnson & Johnson); Dr. Saad, receiving consulting fees from Amgen, Novartis, Sanofi-Aventis, and AstraZeneca and receiving payment for the development of educational presentations from Amgen and Novartis; Dr. Staffurth, receiving consulting fees from Pierre Fabre Laboratories and Ortho Biotech Oncology Research and Development, receiving travel support from Sanofi-Aventis, and holding stock in Johnson & Johnson; Dr. Harland, receiving consulting fees from Sanofi-Aventis and travel support from Ortho Biotech Oncology Research and Development; Dr. Flaig, receiving consulting fees from Sanofi-Aventis and lecture fees from Amgen; Dr. Sternberg, receiving consulting fees and travel support from Ortho Biotech Oncology Research and Development; Dr. Fléchon, receiving travel support from Novartis, Bayer, Pfizer, and Ortho Biotech Oncology Research and Development, serving as a board member for Novartis, Sanofi-Aventis, and Ferring, and receiving payment for the development of educational presentations from Novartis, AstraZeneca, Bayer, and Pfizer; Dr. Efstathiou, receiving consulting fees and travel support from Janssen-Cilag; and Dr. Scher, receiving consulting fees from Aragon, Bristol-Myers Squibb, Exelixis, Foundation Medicine, Genentech, and Medivation, consulting fees and travel support from Amgen, Ortho Biotech Oncology Research and Development, Dendreon, Enzon, Millenium, Novartis, Roche, and Sanofi-Aventis, travel support from AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, Medivation, and Veridex, and grant support from Bristol-Myers Squibb, Ortho Biotech Services, Medivation, and Veridex, and holding stock in Eli Lilly, Genta, and Johnson & Johnson. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the patients who volunteered to participate in this study; the study-site staff members who cared for them; the members of the independent data and safety monitoring committee: Ian Tannock, M.D., Ph.D. (chair), Nick Thatcher, M.D., Sten Nilsson, M.D., and Ralph Harkins, Ph.D.; the members of the Cougar scientific advisory board: Arie Belldegrun, M.D., Eric Small, M.D., Phil Kantoff, M.D., Matthew Smith, M.D., Ph.D., Tia Higano, M.D., Nicholas Vogelzang, M.D., Michael Carducci, M.D., William Kelly, D.O., and Richard Auchus, M.D.; Carlo Messina, M.D., for assistance with the protocol; the sponsor staff involved in data collection and analyses: Esther Welkowsky, B.S., Antonieta Sosa, M.Sc., Amy Goodowitz Levin, R.N., B.S.N., Denise Kimball R.N., B.S.N., and Youn Choi Park, Ph.D.; and Namit Ghildyal, Ph.D., for editorial assistance in the development of the manuscript.

Source Information

From the Institute of Cancer Research and Royal Marsden Hospital, Sutton (J.S.B., A.Z., D.B.), Institute of Cancer Sciences, Glasgow (R.J.J.), Cardiff University, Velindre Hospital, Cardiff (J.N.S.), and Cambridge (H.P.) — all in the United Kingdom; M.D. Anderson Cancer Center, Houston (C.J.L., E.E.); Ortho Biotech Oncology Research and Development (a unit of Umbrella Biotechnology), Los Angeles (A.M., N.C., T.K., C.M.H.); Institut Gustave Roussy, Villejuif (K.F., Y.L.), and Centre Léon Bérard, Lyon (A.F.) — both in France; Cross Cancer Institute, Edmonton, AB (S.N.), BC Cancer Agency, Vancouver Cancer Centre, Vancouver (K.N.C.), University of Calgary, Calgary, AB (T.C.), and BC Cancer Agency, Centre for the Southern Interior, Kelowna (S.L.E.) — all in Canada; Oncology Hematology Consultants, Sarasota, FL (L.C.); Nevada Cancer Institute, Las Vegas (O.B.G.); University of Montreal, Montreal (F.S.); Haematology and Oncology Clinics of Australasia, Milton, Australia (P.M.); UCL Cancer Institute, London (S.H.); University of Colorado Cancer Center, Aurora (T.W.F.); Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas (T.E.H.); Sarah Cannon Research Institute, Nashville (J.D.H.); Helen Diller Family Comprehensive Cancer Center, University of California–San Francisco, San Francisco (C.J.R.); San Camillo and Forlanini Hospitals, Rome (C.N.S.); Georgia Cancer Specialists, Atlanta (M. Saleh); Prostate Oncology Specialists, Marina del Rey, CA (M. Scholz); and Memorial Sloan-Kettering Cancer Center, and Weill Cornell Medical College, New York (H.I.S.).

Address reprint requests to Dr. de Bono at the Institute of Cancer Research and Royal Marsden Hospital, Downs Rd., Sutton, Surrey SM2 5PT, United Kingdom.

Additional COU-AA-301 investigators are listed in the Supplementary Appendix, available at NEJM.org.